About ADP/ATP translocase 2
ADP/ATP translocase 2 (SLC25A5) is a protein
from Homo sapiens identified by UniProt accession
P05141, 298 residues long.
MolForge cross-references it against 0 known binders and
107 disease associations.
Target properties
| Protein name | ADP/ATP translocase 2 |
|---|
| UniProt accession | P05141 |
|---|
| Gene | SLC25A5 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 298 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Approved drugs hitting this target (2)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (107)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.48
- HIV infection · score 0.37
- neuroinflammatory disorder · score 0.26
- mitochondrial DNA measurement · score 0.26
- clear cell renal carcinoma · score 0.17
- gonorrhea · score 0.07
- neoplasm · score 0.06
- cancer · score 0.06
- acute quadriplegic myopathy · score 0.02
- hepatocellular carcinoma · score 0.01
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-P05141-F1 | alphafold | PREDICTED | 91.72 | — |
Amino-acid sequence (298 residues)
MTDAAVSFAK DFLAGGVAAA ISKTAVAPIE RVKLLLQVQH ASKQITADKQ YKGIIDCVVR IPKEQGVLSF WRGNLANVIR YFPTQALNFA FKDKYKQIFL GGVDKRTQFW LYFAGNLASG GAAGATSLCF VYPLDFARTR LAADVGKAGA EREFRGLGDC LVKIYKSDGI KGLYQGFNVS VQGIIIYRAA YFGIYDTAKG MLPDPKNTHI VISWMIAQTV TAVAGLTSYP FDTVRRRMMM QSGRKGTDIM YTGTLDCWRK IARDEGGKAF FKGAWSNVLR GMGGAFVLVL YDEIKKYT
Explore ADP/ATP translocase 2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets